EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSPKIG00000000841
Gene Symbol: GABRA2
4 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSPKIG00000005196
Gene Symbol: GABRA2
2 Cross references
186 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSPKIG00000008211
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSPKIG00000005112
Gene Symbol: GABRA4
4 Cross references
130 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSPKIG00000023202
Gene Symbol: GABRA5
1 Cross references
266 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSPKIG00000002822
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6a

Ensembl ID : ENSPKIG00000001207
Gene Symbol: GABRA6A
2 Cross references
69 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSPKIG00000001239
Gene Symbol: GABRB2
2 Cross references
269 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2a

Ensembl ID : ENSPKIG00000002861
Gene Symbol: GABRB2A
2 Cross references
135 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSPKIG00000023229
Gene Symbol: GABRB3
3 Cross references
261 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSPKIG00000005448
Gene Symbol: GABRB3
4 Cross references
261 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSPKIG00000012348
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).